Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fees Face Opposition From Key House Appropriator DeLauro

Executive Summary

The chairwoman of the House subcommittee that oversees funding for FDA does not support user fees to finance reviews of generic drug applications

You may also be interested in...



Generic Drug Fees Could Be Based On Product Complexity

FDA seeks comments at Sept. 17 public hearing on issues surrounding development of an ANDA user fee program, including whether applications for more complex products should carry a higher fee and whether fees should be used to support postmarketing safety oversight.

Avandia Aftershocks: Will FDA Drug Safety Review Structures Crumble?

Rep. Rosa DeLauro's, D-Conn., hearing on the safety of GlaxoSmithKline's diabetes drug Avandia has ratcheted up the pressure on FDA to make broad reforms of its review structure, but the congresswoman has been careful not to urge a particular course of action for the agency

Avandia Aftershocks: Will FDA Drug Safety Review Structures Crumble?

Rep. Rosa DeLauro's, D-Conn., hearing on the safety of GlaxoSmithKline's diabetes drug Avandia has ratcheted up the pressure on FDA to make broad reforms of its review structure, but the congresswoman has been careful not to urge a particular course of action for the agency

Related Content

Topics

UsernamePublicRestriction

Register

PS052185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel